American Century Companies Inc. Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

American Century Companies Inc. boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 18.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 157,409 shares of the biopharmaceutical company’s stock after buying an additional 24,395 shares during the quarter. American Century Companies Inc.’s holdings in Catalyst Pharmaceuticals were worth $3,285,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Pacer Advisors Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Boston Partners grew its position in Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock worth $27,325,000 after purchasing an additional 16,601 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock valued at $26,023,000 after buying an additional 79,182 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Catalyst Pharmaceuticals by 74.3% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after buying an additional 312,000 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company’s stock worth $15,100,000 after buying an additional 9,194 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 4.3 %

NASDAQ CPRX opened at $23.07 on Monday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $26.16. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 3.31 and a beta of 0.79. The company’s 50 day moving average is $22.78 and its two-hundred day moving average is $21.96.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Stephens reiterated an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.